natgillin/translations-raw huggingface dataset:
Blood glucose selfmonitoring is necessary to adjust the dose of sulphonylurea or insulin, particularly when Byetta therapy is started and insulin is reduced.
Bolnikov samonadzor glukoze v krvi pa je potreben za prilagajanje odmerka sulfonilsečnine ali insulina, zlasti ob začetku zdravljenja z zdravilom Byetta in zmanjšanju odmerka insulina.
Blood glucose self-monitoring is necessary to adjust the dose of sulphonylurea and insulin, particularly when Victoza therapy is started and insulin is reduced.
Samokontrola glukoze v krvi pa je potrebna za prilagajanje odmerka sulfonilsečnine in insulina, zlasti ob začetku zdravljenja z zdravilom Victoza in zmanjšanju odmerka insulina.
Blood glucose self-monitoring is necessary to adjust the dose of sulphonylurea and of insulin particularly when prolonged-release exenatide therapy is started and insulin is reduced.
Bolnikov samonadzor glukoze v krvi pa je potreben za prilagajanje odmerka sulfonilsečnine in insulina, zlasti ob začetku zdravljenja z eksenatidom v obliki s podaljšanim sproščanjem in zmanjšanju odmerka insulina.
What you need to know before you take <medicinal product> Warnings and precautions <Medicinal product> can cause harm to an unborn baby.
Kaj morate vedeti, preden boste vzeli zdravilo <ime zdravila> Opozorila in previdnostni ukrepi
Strength Pharmaceutical Form Route of Administration Packaging
Jakost Farmacevtska oblika Pot uporabe
Immediate Packaging Pack size
Pot uporabe Stična ovojnina Velikost pakiranja plastenka (HDPE)
The European Commission granted a marketing authorisation valid throughout the European Union for Celsentri on 18 September 2007.
Evropska komisija je dovoljenje za promet z zdravilom Celsentri, veljavno po vsej Evropski uniji, izdala 18. septembra 2007.
What measures are being taken to ensure the safe and effective use of Celsentri?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Celsentri?
The full EPAR for Celsentri can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Celsentri je na voljo na spletni strani agencije ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Other information about Celsentri
Druge informacije o zdravilu Celsentri
The safety profile of Celsentri is considered acceptable and no major concerns have been identified.
Varnostni profil zdravila Celsentri je bil ocenjen kot sprejemljiv, saj ni bilo ugotovljenih nobenih večjih zadržkov.
In adults, the recommended dose is 150, 300 or 600 mg twice a day, depending on the other medicines that the patient is taking.
Priporočeni odmerek pri odraslih je 150, 300 ali 600 mg dvakrat na dan, odvisno od drugega zdravila, ki ga bolnik jemlje.
What is Celsentri and what is it used for?
Kaj je zdravilo Celsentri in za kaj se uporablja?
Celsentri is available as tablets (25, 75, 150 and 300 mg) and as a liquid (20 mg/ml) to be taken by mouth.
Zdravilo Celsentri je na voljo v obliki tablet (25, 75, 150 in 300 mg) in tekočine (20 mg/ml) za peroralno uporabo.
Based on these data, effectiveness is expected to be similar in children and adults.
Na podlagi teh podatkov je mogoče pričakovati, da je učinkovitost zdravila pri otrocih in odraslih podobna.
The Agency's Committee for Medicinal Products for Human Use (CHMP) therefore decided that Celsentri's benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Celsentri večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The patients had previously taken other treatments for HIV for at least six months, but these had stopped working.
Bolniki so predhodno vsaj šest mesecev jemali druga zdravila za zdravljenje okužbe z virusom HIV, vendar so ta prenehala delovati.
It is not intended to provide practical advice on how to use Celsentri.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
This is a summary of the European public assessment report (EPAR) for Celsentri.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Celsentri.
Patients who have reduced kidney function may need to take Celsentri less frequently.
Bolniki, ki imajo okrnjeno delovanje ledvic, bodo morda morali zdravilo Celsentri jemati manj pogosto.
What benefits of Celsentri have been shown in studies?
Kakšne koristi je zdravilo Celsentri izkazalo v študijah?
Celsentri tablets must not be used in patients who are hypersensitive (allergic) to peanut and soya.
Zdravila Celsentri v obliki tablet ne smejo uporabljati bolniki, ki so preobčutljivi za (alergični na) arašide in sojo.
Similar results were also seen when looking at the patients who continued treatment with Celsentri 300 mg twice a day for 48 weeks.
Podobni rezultati so bili zabeleženi ob spremljanju bolnikov, ki so zdravljenje z zdravilom Celsentri v odmerku 300 mg dvakrat na dan nadaljevali še nadaljnjih 48 tednov.
What are the risks associated with Celsentri?
Kakšna tveganja so povezana z zdravilom Celsentri?
Why is Celsentri approved?
Zakaj je bilo zdravilo Celsentri odobreno?
In children, the dose is based on body weight.
Pri otrocih je odmerek odvisen od telesne mase.
The most common side effects with Celsentri (which may affect up to 1 in 10 people) are nausea (feeling sick), diarrhoea, fatigue (tiredness) and headache.
Najpogostejši neželeni učinki zdravila Celsentri (ki lahko prizadenejo največ 1 osebo od 10) so navzeja (slabost), driska, utrujenost in glavobol.
The active substance in Celsentri, maraviroc, is a ‘CCR5 antagonist'.
Zdravilna učinkovina zdravila Celsentri, maravirok, je „antagonist CCR5“.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Celsentri have been included in the summary of product characteristics and the package leaflet.
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Celsentri upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
All of the patients also took ‘optimised background therapy' (a combination of other HIV medicines chosen for each patient to increase the chances of reducing the levels of HIV in the blood).
Vsi bolniki so sočasno prejemali „optimizirano osnovno terapijo“ (kombinacijo drugih zdravil za zdravljenje okužbe z virusom HIV, izbranih za vsakega posamičnega bolnika posebej zaradi povečanja možnosti znižanja ravni virusa HIV v krvi).
Celsentri does not cure HIV infection or AIDS, but it may hold off the damage to the immune system and the development of infections and diseases associated with AIDS.
Zdravilo Celsentri ne ozdravi okužbe z virusom HIV ali aidsa, lahko pa upočasni slabšanje imunskega sistema ter prepreči razvoj okužb in bolezni, povezanih z aidsom.
For more information about treatment with Celsentri, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Celsentri preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Celsentri has been shown to be effective at reducing the levels of HIV in the blood in two main studies involving a total of 1,076 mostly adult patients with CCR5-tropic HIV infection.
Zdravilo Celsentri se je izkazalo za učinkovito pri zmanjševanju ravni virusa HIV v krvi v dveh glavnih študijah, v katerih je sodelovalo skupno 1 076 večinoma odraslih bolnikov, okuženih s CCR5tropnim HIV.
Celsentri is an HIV medicine used to treat patients from 2 years of age and weighing at least 10 kg who are infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Celsentri je zdravilo proti okužbi z virusom HIV, ki se uporablja pri bolnikih, starejših od dveh let in s telesno maso vsaj 10 kg, ki so okuženi z virusom humane imunske pomanjkljivosti tipa 1 (HIV-1), tj. virusom, ki povzroča sindrom pridobljene imunske pomanjkljivosti (aids).
This means that the virus, when infecting a cell, attaches to a specific protein called CCR5 on the surface of the cell.
To pomeni, da se virus ob okužbi celice veže na posebno beljakovino, imenovano CCR5, ki se nahaja na površini celice.
As HIV can only reproduce itself within cells, Celsentri, taken in combination with other HIV medicines, reduces the level of CCR5-tropic HIV, and keeps it at a low level.
Ker se virus HIV lahko razmnožuje samo znotraj celic, zdravilo Celsentri v kombinaciji z drugimi zdravili proti okužbi z virusom HIV zmanjšuje raven CCR5-tropnega HIV in jo ohranja na nizki ravni.
For practical information about using Celsentri, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Celsentri naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Additional data indicate that Celsentri given at a suitable dose to children is handled by their body in the same way as in adults.
Dodatni podatki kažejo, da pri otrocih, ki prejemajo ustrezen odmerek zdravila Celsentri, telo enako presnavlja zdravilo kot pri odraslih.
Celsentri cannot work against viruses that attach to another protein called CXCR4, or when it can attach to both CCR5 and CXCR4.
Zdravilo Celsentri ni učinkovito proti virusom, ki se vežejo na drugo beljakovino, imenovano CXCR4, ali na obe beljakovini, CCR5 in CXCR4.
Celsentri used in combination with other HIV medicines has been shown to be effective at reducing the levels of HIV in the blood in adults, and similar effects are expected in children.
Uporaba zdravila Celsentri v kombinaciji z drugimi zdravili za zdravljenje okužbe z virusom HIV se je izkazala kot učinkovita pri zmanjševanju ravni virusa HIV v krvi pri odraslih, podoben učinek pa se pričakuje tudi pri otrocih.
Celsentri can only be obtained with a prescription and treatment should be started by a doctor who has experience in the management of HIV infection.
Predpisovanje in izdaja zdravila Celsentri je le na recept, zdravljenje z njim pa mora uvesti zdravnik, ki ima izkušnje z zdravljenjem okužbe z virusom HIV.
CCR5-tropic HIV uses this protein to enter the cells.
CCR5-tropni HIV s pomočjo te beljakovine vstopa v celico.
In the studies Celsentri was compared with placebo (a dummy treatment).
V obeh študijah so zdravilo Celsentri primerjali s placebom (zdravilom brez zdravilne učinkovine).
Before treatment, the doctor must check that the patient's blood only shows infection with CCR5-tropic virus.
Pred začetkom zdravljenja mora zdravnik preveriti, ali je v bolnikovi krvi prisoten le CCR5-tropni HIV.
It blocks the CCR5 protein on the surface of the cells in the body that HIV infects.
Ta zavira beljakovino CCR5 na površini celic telesa, ki so okužene z virusom HIV.
Looking at the results of the two studies taken together, the levels of HIV in the blood had fallen by an average of 99% after 24 weeks in the patients adding Celsentri to optimised background therapy, compared with 90% in those adding placebo.
Analiza rezultatov obeh študij je pokazala, da so ravni virusa HIV v krvi po 24 tednih padle za povprečno 99 % pri bolnikih, ki so kot dodatek k optimizirani osnovni terapiji jemali zdravilo Celsentri, medtem ko so pri bolnikih, ki so kot dodatek jemali placebo, ravni padle za 90 %.
Celsentri contains the active substance maraviroc.
Zdravilo Celsentri vsebuje zdravilno učinkovino maravirok.
The proportion of patients who had undetectable levels of HIV in their blood after 24 weeks was about 45% with Celsentri compared to 23% with placebo.
Delež bolnikov z nezaznavnimi ravnmi virusa HIV v krvi po 24 tednih je bil 45 % v skupini, ki je prejemala zdravilo Celsentri, in 23 % v skupini, ki je prejemala placebo.
For the full list of all side effects reported with Celsentri, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Celsentri, glejte navodilo za uporabo.
Celsentri is used in combination with other HIV medicines, and only in patients who have been treated for HIV infection before and only when the HIV-1 they are infected with is ‘CCR5-tropic', which is determined by a blood test.
Zdravilo Celsentri se uporablja v kombinaciji z drugimi zdravili proti okužbi z virusom HIV, in sicer samo pri bolnikih, ki so predhodno že bili zdravljeni zaradi okužbe z virusom HIV in pri katerih je prisoten le CCR5-tropni HIV-1, kar se ugotavlja s krvnimi preiskavami.
How is Celsentri used?
Kako se zdravilo Celsentri uporablja?
How does Celsentri work?
Kako zdravilo Celsentri deluje?
By attaching itself to the protein, Celsentri prevents the virus from entering the cells.
Zdravilo Celsentri z vezavo na to beljakovino preprečuje vstop virusa v celico.
The European Commission granted a marketing authorisation valid throughout the European Union for Aprovel on 27 August 1997.
Evropska komisija je dovoljenje za promet z zdravilom Aprovel, veljavno po vsej Evropski uniji, odobrila 27. avgusta 1997.
Other information about Aprovel
Druge informacije o zdravilu Aprovel
The full EPAR for Aprovel can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Aprovel je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Aprovel was used for two years or more.
Bolniki so zdravilo Aprovel jemali dve leti ali več.
What benefit has Aprovel shown during the studies?
Kakšne koristi je zdravilo Aprovel izkazalo med študijami?
The usual recommended dose of Aprovel is 150 mg once a day.
Običajni priporočeni odmerek zdravila Aprovel znaša 150 mg enkrat dnevno.
This is a summary of the European public assessment report (EPAR) for Aprovel.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Aprovel.
If the blood pressure is not sufficiently controlled, the dose can be increased to 300 mg a day or other medicines for hypertension can be added, such as hydrochlorothiazide.
Če krvni tlak ni zadostno nadzorovan, se odmerek lahko poveča na 300 mg dnevno ali dodajo druga zdravila za zdravljenje visokega krvnega tlaka, kot je npr. hidroklorotiazid.
For more information about treatment with Aprovel, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Aprovel preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
What is the risk associated with Aprovel?
Kakšna tveganja so povezana z zdravilom Aprovel?
The CHMP decided that Aprovel's benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Aprovel večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Aprovel.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Aprovel, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
In this study, Aprovel was compared with placebo and with amlodipine.
V tej študiji so zdravilo Aprovel primerjali s placebom in amlodipinom.
Aprovel is a medicine that contains the active substance irbesartan.
Aprovel je zdravilo, ki vsebuje zdravilno učinkovino irbesartan.
For the treatment of kidney disease, Aprovel was studied in two large studies involving a total of 2,326 patients with type 2 diabetes.
Zdravilo Aprovel so glede zdravljenja ledvičnega obolenja preučevali v okviru dveh velikih študij, ki sta vključevali skupno 2 326 bolnikov s sladkorno boleznijo tipa 2.
Aprovel is used in adults who have essential hypertension (high blood pressure).
Zdravilo Aprovel se uporablja pri odraslih, ki imajo esencialno hipertenzijo (visok krvni tlak).
Aprovel must not be used in people who are hypersensitive (allergic) to irbesartan or any of the other ingredients.
Zdravila Aprovel ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) irbesartan ali katero koli drugo sestavino zdravila.
The most common side effect with Aprovel (seen in more than 1 patient in 10) is hyperkalaemia (high blood potassium levels).
Najpogostejši neželeni učinek zdravila Aprovel (opažen pri več kot 1 bolniku od 10) je hiperkaliemija (visoka raven kalija v krvi).
The active substance in Aprovel, irbesartan, is an ‘angiotensin II receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II.
Zdravilna učinkovina v zdravilu Aprovel, irbesartan, je antagonist receptorjev angiotenzina II, kar pomeni, da v telesu preprečuje delovanje hormona, imenovanega angiotenzin II.
Why has Aprovel been approved?
Zakaj je bilo zdravilo Aprovel odobreno?
Aprovel was compared with placebo (a dummy treatment) in 712 patients and with other medicines for hypertension (atenolol, enalapril or amlodipine) in 823 patients.
Zdravilo Aprovel so pri 712 bolnikih primerjali s placebom (zdravilom brez zdravilne učinkovine), pri 823 bolnikih pa z drugimi zdravili za zdravljenje visokega krvnega tlaka (atenololom, enalaprilom ali amlodipinom).
For the full list of all side effects reported with Aprovel, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Aprovel, glejte navodilo za uporabo.
Aprovel in combination with aliskirencontaining medicines (used to treat essential hypertension) must not be used in patients with diabetes, or moderate or severe kidney impairment.
Zdravilo Aprovel se v kombinaciji z zdravili, ki vsebujejo aliskiren (ki se uporablja za zdravljenje esencialne hipertenzije), ne sme uporabljati pri bolnikih s sladkorno boleznijo ali zmerno do hudo ledvično okvaro.
In patients with hypertension and type 2 diabetes, Aprovel is added to some other treatments for hypertension.
Pri bolnikih z visokim krvnim tlakom in sladkorno boleznijo tipa 2 se zdravilo Aprovel dodaja nekaterim drugim zdravilom za zdravljenje visokega krvnega tlaka.
In the first kidney disease study, Aprovel was more effective than placebo at reducing the risk of developing kidney damage as measured by protein excretion.
V prvi študiji ledvičnega obolenja je bilo zdravilo Aprovel učinkovitejše od placeba pri zmanjševanju tveganja za razvoj poškodbe ledvic, merjene na podlagi izločanja beljakovin.
In the blood pressure studies, Aprovel was more effective than placebo at reducing diastolic blood pressure and had similar effects to the other medicines for hypertension.
V študijah krvnega tlaka je bilo zdravilo Aprovel pri zniževanju diastoličnega krvnega tlaka učinkovitejše od placeba in je imelo podobne učinke kot druga zdravila za zdravljenje visokega krvnega tlaka.
The second study looked at whether Aprovel increased the time taken until the patients' blood creatinine levels had doubled (a marker of kidney disease), until they needed a kidney transplant or dialysis, or until they died.
V drugi študiji so preučevali, ali zdravilo Aprovel podaljša čas, v katerem se raven kreatinina (označevalca ledvičnega obolenja) v krvi bolnikov podvoji, čas do pojava potrebe po presaditvi ledvic ali dializi oziroma čas do nastopa smrti.
Aprovel was originally studied in 11 trials for its effects on blood pressure.
Učinke zdravila Aprovel na krvni tlak so prvotno preučevali v 11 preskušanjih.
How has Aprovel been studied?
Kako je bilo zdravilo Aprovel raziskano?
Aprovel is also used to treat kidney disease in adults with hypertension and type 2 diabetes.
Zdravilo Aprovel se uporablja tudi za zdravljenje ledvičnega obolenja pri odraslih z visokim krvnim tlakom in sladkorno boleznijo tipa 2.
In the second kidney disease study, Aprovel reduced the relative risk of a doubling of blood creatinine levels, needing a kidney transplant or dialysis, or death during the study by 20% in comparison with placebo.
V drugi študiji ledvičnega obolenja je zdravilo Aprovel v primerjavi s placebom za 20 % zmanjšalo relativno tveganje za podvojitev ravni kreatinina v krvi, za pojav potrebe po presaditvi ledvic ali dializi ali za nastop smrti med študijo.
How does Aprovel work?
Kako zdravilo Aprovel deluje?
What is Aprovel used for?
Za kaj se zdravilo Aprovel uporablja?
What is Aprovel?
Kaj je zdravilo Aprovel?
How is Aprovel used?
Kako se zdravilo Aprovel uporablja?
- are taking any of the following medicines used to treat high blood pressure:
- jemljete katero od naslednjih zdravil, ki se uporabljajo za zdravljenje visokega krvnega tlaka:
It is important to keep taking Ipreziv every day.
Pomembno je, da zdravilo Ipreziv vzamete vsak dan.
Therefore do not stop taking Ipreziv without first talking to your doctor about alternative treatment options.
Zdravila Ipreziv ne nehajte jemati, ne da bi se prej s svojim zdravnikom pogovorili o alternativnih možnostih zdravljenja.
Older people (65 years and over)
Posebne populacije Starejši (65 let in starejši)
(It is also better to avoid Ipreziv in early pregnancy - see pregnancy section).
(Zdravilu Ipreziv se je bolje izogibati tudi v zgodnji nosečnosti glejte poglavje Nosečnost).
If symptomatic hypotension should occur, supportive treatment should be instituted and vital signs monitored.
Če pride do simptomatične hipotenzije, je treba uvesti podporno zdravljenje in nadzirati vitalne znake.
However, when taking any antihypertensive it should be taken into account that occasionally dizziness or tiredness may occur.
Vendar pa je pri uporabi kateregakoli antihipertenziva treba upoštevati, da se lahko občasno pojavi omotica ali utrujenost.
However some people may feel tired or dizzy when taking Ipreziv and if this happens to you, do not drive or use any tools or machines.
Vendar lahko nekateri bolniki med jemanjem zdravila Ipreziv čutijo utrujenost ali omotico in če se to dogaja vam, ne vozite in ne uporabljajte orodij ali strojev.
If you stop taking Ipreziv, your blood pressure may increase again.
Če prenehate z jemanjem zdravila Ipreziv, lahko krvni tlak znova naraste.
You can take Ipreziv with or without food.
Zdravilo Ipreziv lahko jemljete skupaj s hrano ali brez nje.
These are ranked by frequency, using the following convention: very common (≥ 1/10); common (≥ 1/100, < 1/10); uncommon (≥ 1/1,000, < 1/100); rare (≥ 1/10,000, < 1/1,000); very rare (< 1/10,000), including isolated reports.
zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do < 1/1.000); zelo redki (< 1/10.000), vključno s posameznimi primeri.
See also information under the heading “Do not take Ipreziv”.
Glejte tudi informacije pod naslovom “Ne jemljite zdravila Ipreziv”
WHAT IPREZIV IS AND WHAT IT IS USED FOR
Kaj je zdravilo Ipreziv in za kaj ga uporabljamo
Your doctor will normally advise you to stop taking Ipreziv before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Ipreziv.
Zdravnik vam bo praviloma svetoval, da zdravilo Ipreziv prenehate jemati, preden boste zanosili ali takoj ko boste vedeli, da ste noseči, in vam svetoval, da namesto zdravila Ipreziv jemljete drugo zdravilo.
Therefore, Ipreziv should not be given to children or adolescents.
Zdravila Ipreziv se ne sme dajati otrokom ali mladostnikom.
The safety and efficacy of Ipreziv in children and adolescents 0 to < 18 years have not yet been established.
Varnost in učinkovitost zdravila Ipreziv pri otrocih in mladostnikih starih 0 do < 18 let še nista bili dokazani.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE IPREZIV
Kaj morate vedeti, preden boste vzeli zdravilo Ipreziv
The frequency of this event is highest when amlodipine is taken alone.
Pogostnost tega neželenega učinka je največja, če se jemlje samo amlodipin.
If you stop taking Ipreziv
Če ste prenehali jemati zdravilo Ipreziv
Therefore, the use of Ipreziv is not recommended in these patients.
Uporabe zdravila Ipreziv pri teh bolnikih zato ne priporočamo.